Critical Survey: Avalo Therapeutics (NASDAQ:AVTX) and Vericel (NASDAQ:VCEL)

Avalo Therapeutics (NASDAQ:AVTX) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Risk & Volatility

Avalo Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Avalo Therapeutics and Vericel, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1	2	11	0	2.71
Vericel	0	1	5	1	3.00

Avalo Therapeutics currently has a consensus price target of $36.82, indicating a potential upside of 378.16%. Vericel has a consensus price target of $62.00, indicating a potential upside of 7.98%. Given Avalo Therapeutics’ higher possible upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Vericel.

Insider and Institutional Ownership

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Avalo Therapeutics and Vericel”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60,000.00	7,420.23	-$78.26 million	($2.52)	-3.06
Vericel	$276.26 million	10.61	$16.52 million	$0.64	89.72

Vericel has higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avalo Therapeutics and Vericel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-34.21%	-29.84%
Vericel	10.27%	9.09%	6.68%

Summary

Vericel beats Avalo Therapeutics on 11 of the 15 factors compared between the two stocks.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.

About Vericel

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.